Initial HIV Therapy and Weight Gain

Can Doravirine Control HIV With Less Weight Gain?

The study highlighted by MedPage Today involved treatment-naive adults, meaning participants had not previously received antiretroviral therapy. A regimen anchored by doravirine, a non-nucleoside reverse transcriptase inhibitor, reportedly performed as well virologically as a regimen based on dolutegravir, an integrase strand transfer inhibitor. Participants receiving doravirine experienced significantly less weight gain during the study period.

This distinction matters because weight gain after starting antiretroviral therapy can reflect several overlapping factors, including recovery from untreated HIV, baseline body weight, accompanying medicines, lifestyle, and the metabolic effects of individual drug combinations. A difference on the scale does not automatically establish a reduction in diabetes or cardiovascular events, so longer follow-up is needed to determine whether the finding produces meaningful long-term health benefits.

How Do Doravirine and Dolutegravir Work?

Doravirine inhibits the reverse transcriptase enzyme that HIV uses to convert its genetic material into DNA. It is used with other antiretroviral medicines and is also available in a fixed-dose combination with lamivudine and tenofovir disoproxil fumarate. Dolutegravir blocks HIV integrase and is widely used because of its antiviral potency and relatively high barrier to resistance.

The medicines also have different interaction profiles. Strong CYP3A enzyme inducers can substantially reduce doravirine exposure, while mineral supplements and antacids containing polyvalent cations can interfere with dolutegravir absorption unless doses are appropriately separated. Clinicians must review every prescription medicine, supplement, resistance result, and coexisting condition before choosing either approach.

Should Weight Concerns Change a Patient's First HIV Regimen?

Current HIV treatment guidance emphasizes selecting a complete regimen that can rapidly achieve and maintain an undetectable viral load. Integrase inhibitor-based combinations remain important initial options for many patients, and this study does not show that dolutegravir is unsuitable for everyone. Instead, the findings strengthen the case for discussing metabolic priorities when more than one clinically appropriate regimen is available.

A patient's hepatitis B status is particularly important because stopping or omitting medicines active against both HIV and hepatitis B can lead to hepatitis flares. Pregnancy considerations, kidney function, cardiovascular risk, previous resistance, adherence needs, and access also affect treatment decisions. Patients concerned about weight should discuss monitoring and alternatives with their HIV clinician rather than stopping or switching therapy independently.